Matthew L. Posard sold $568k of HALO
director at HALOZYME THERAPEUTICS, INC.. 5,230 shares at an average of $108.54, traded Oct 1, 2026, filed Oct 2, 2026.
Score components
- +15RoleDirector
- +19Trade size$568k at market
- 0Share of holdings soldSold 8.9% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-26-000133, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -730 | $107.17 | $78k | 58,109 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -3,300 | $108.45 | $358k | 54,809 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -1,100 | $109.57 | $121k | 53,709 | 10 d ago |
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $110.04 | $11k | 53,609 | 10 d ago |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 13Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $174k 2,227 shares | -9% | |
| 37Weak | HALOZYME THERAPEUTICS, INC. | Nicole LaBrosse SVP, CHIEF FINANCIAL OFFICER | $1.5M 20,000 shares | -45% | |
| 30Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $4.4M 60,000 shares | -8% | |
| 24Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $295k 4,000 shares | -8% | |
| 15Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.8M 60,000 shares | -8% | |
| 15Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.4M 60,000 shares | -8% | |
| 15Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.2M 60,000 shares | -8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.